Is BioVaxys Technology Corp. (BVAXF) a Buy, Sell, or Hold?
OTC : BVAXF
BioVaxys Technology Corp.
$0.1199 USD
$0.02 (19.42%)
- Volume
- 7.48K
- Average Volume
- 58.72K
- Market Capitalization
- $3.5M
- P/E Ratio
- -0.59
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.27
- Year Low
- $0.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.28
Company Overview
OTC
James Christopher Passin
Biotechnology
Healthcare
BVAXF
3
CA
USD
Liquidity Metrics
-0.04
0.28
0.28
0.00
0.00
Sales & Valuation
-$
0.00
-0.56
-1.04
-0.07
Profitability
-$0.20199999999999999
-$3.95M
0.00%
0.00%
121.88%
-237.77%
P/E Metrics
-0.59
0.03
0.03
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-50.56
1/9
-$3.64M
$1.39M
$5.03M
-$5.51M
Key Metrics (TTM)
$2.17M
0.00
-0.64
0.28
121.88%
95.65%
-161.56%
-95.92%
0 days
Company Executives
| Name | Title |
|---|---|
| Christopher Cherry | Chief Financial Officer |
| James Christopher Passin | Co-Founder, Chief Executive Officer, & Director |
| Kenneth E. Kovan | Co-Founder, President & Chief Operating Officer |
| David Berd | Co-Founder & Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About BioVaxys Technology Corp. (OTC:BVAXF) Stock
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, BioVaxys offers CoviDTH, an immunodiagnostic tool developed to detect immune system responses in individu ... als previously exposed to SARS-CoV-2. To support its development initiatives, BioVaxys has established several strategic collaborations. It holds a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, crucial components for BVX-0320 and CoviDTH. The company also has a research collaboration for BVX-0320 with The Ohio State University, Wexner School of Medicine. Additionally, Bioanalytical Systems, Inc. is conducting preclinical toxicology studies for BioVaxys' CoviDTH immunodiagnostic under a separate agreement. The company's operations are headquartered in Vancouver, Canada.
2026-05-01 08:00:00
Unique MRI Study Shows How the Combination Exerts its Effect VANCOUVER, BC – TheNewswire - May 1, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of a study that further validates the immune response mechanism from a combination of its maveropepimut-S (MVP-S) immunotherapeutic vaccine combined with a checkpoint inhibitor and low dose intermittent cyclophosphamide in ovarian cancer. Led by Dr Kimberly Brewer of the IWK Health Center and Associate Professor, Faculty of Medicine-Dalhousie University, the study is entitled “MRI of Combination Immunotherapy in an Epithelial Ovarian Cancer Preclinical Model” and is published in the April 2026 edition of Nature/NPJ Imaging.
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
2026-04-28 16:30:00
VANCOUVER, BC, April 28 2026 - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, its related management's discussion and analysis, and the Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. As a result of the delay in filing the Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2026, its related management's discussion and analysis, and related filings (collectively, the “ Interim Filings ”). Under National Instrument 51-102, the Interim Filings were required to be made not later than April 1, 2026.
2026-04-27 08:00:00
VANCOUVER, BC, April 27th, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0) today announced the acceptance of an abstract related to the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of BioVaxys' MVP-S with pembrolizumab (Keytruda™) and cyclophosphamide in patients with recurrent epithelial ovarian cancer for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, May 29th-June 6th, 2026. With over 44,000 expected attendees, including oncologists, researchers, and pharmaceutical professionals, the ASCO Annual Meeting is a top-tier global oncology conference, and is recognized as one of the most significant, high-visibility events for clinical trials, research, and oncology innovation. All accepted ASCO abstracts are published online as a supplement to the Journal of Clinical Oncology (JCO),
Frequently Asked Questions
-
What is the current BioVaxys Technology Corp. (BVAXF) stock price?
-
BioVaxys Technology Corp.(OTC:BVAXF) stock price is $0.1199 in the last trading session. During the trading session, BVAXF stock reached the peak price of $0.267 while $0.0209 was the lowest point it dropped to. The percentage change in BVAXF stock occurred in the recent session was 19.42% while the dollar amount for the price change in BVAXF stock was $0.02.
-
BVAXF's industry and sector of operation?
-
The OTC listed BVAXF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BVAXF?
-
Christopher Cherry | Chief Financial Officer
James Christopher Passin | Co-Founder, Chief Executive Officer, & Director
Kenneth E. Kovan | Co-Founder, President & Chief Operating Officer
David Berd | Co-Founder & Chief Medical Officer
| -
How many employees does BVAXF have?
-
Number of BVAXF employees currently stands at 3. BVAXF operates from 905 West Pender Street, Etobicoke, ON V6C 1L6, CA.
-
Link for BVAXF official website?
-
Official Website of BVAXF is: https://www.biovaxys.com
-
How do I contact BVAXF?
-
BVAXF could be contacted at phone #646 452 7054 and can also be accessed through its website. BVAXF operates from 905 West Pender Street, Etobicoke, ON V6C 1L6, CA.
-
How many shares of BVAXF are traded daily?
-
The average number of BVAXF shares traded daily for last 3 months was 58.72K.
-
What is the market cap of BVAXF currently?
-
The market value of BVAXF currently stands at $3.5M with its latest stock price at $0.1199